Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9039778 | 0.89 | MTNR1A (0.52) | MTNR1APDE4BMTNR1BKDM4ECDC25B | |
| SCHEMBL16755706 | 0.87 | SLC6A2 (0.56) | MTNR1APDE4BMTNR1BKDM4ECDC25B | |
| SCHEMBL9747620 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL2510203 | 0.85 | CDC25B (0.64) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL31613816 | 0.85 | CDC25B (0.64) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL14465841 | 0.85 | PDE4B (0.52) | MTNR1APDE4BMTNR1BKDM4ECDC25B | |
| SCHEMBL11272281 | 0.85 | CDC25B (0.60) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL8661902 | 0.84 | MTNR1A (0.78) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL31613069 | 0.84 | KDR (0.67) | MTNR1AMTNR1BKDM4ECDC25BALDH1A1 | |
| SCHEMBL2509951 | 0.84 | MTNR1A (0.52) | MTNR1AMTNR1BCDC25BAURKAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5424479-A | Reacting aromatic hydroxycarboxylic acids in a mixture with methoxycarboxylic acids with dimethyl sulfate in water | CASSELLA AG (DE) | 1995-06-13 | — | — | US | claimed |
| US-5412150-A | Bromination in presence of oxidizer which can oxidize by-product hydrogen bromide to bromine | CASSELLA AG (DE) | 1995-05-02 | — | — | US | claimed |
| US-4590290-A | REACTING DIMETHYL SULFATE WITH G-HYDROXY-1-NAPHTHOIC ACID | AMERICAN CYANAMID COMPANY (US) | 1986-05-20 | — | — | US | claimed |
| JP-7069993-A | — | — | None | — | — | JP | disclosed |
| WO-2025118034-A1 | COMPOUNDS ACTIVE AT THE SEROTONERGIC 5-HT2A RECEPTOR | Psylo Pty Ltd (AU) | 2025-06-12 | — | — | WO | disclosed |
| EP-1639058-B1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2020-10-21 | — | — | EP | disclosed |
| CN-105838349-B | photochromic compounds | 光学转变公司 | 2019-12-06 | — | — | CN | disclosed |
| EP-2357217-B9 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2357217-B1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-2360224-B1 | Photochromic compounds | TRANSITIONS OPTICAL INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-4568693-A | ANTIDIATBETIC AGENTS | AYERST, MCKENNA & HARRISON, INC. (CA) | 1986-02-04 | — | — | US | disclosed |
| US-4562286-A | Process for preparing methoxytrifluoromethylnaphthoic acid from dimethylnaphthalene | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| US-4560794-A | Process for preparing methoxytrifluoromethylnaphthoic acid from methylnaphthoic acid | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0059596-B1 | N-NAPHTHOYLGLYCINE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| US-4499310-A | 5-Methyl-1-(trifluoromethyl)-2-naphthalenol, process for its preparation and ethers thereof | AYERST, MCKENNA & HARRISON, INC. (CA) | 1985-02-12 | — | — | US | disclosed |
| US-4439617-A | TREATING DIABETES, ENZYME INHIBITOR | AYERST, MCKENNA & HARRISON INC. (CA) | 1984-03-27 | — | — | US | disclosed |
| US-4408077-A | 6-(Lower alkoxy)-5-(trifluoromethyl)-1-naphthalenecarboxaldehydes | AYERST, MCKEENA & HARRISON, INC. (CA) | 1983-10-04 | — | — | US | disclosed |
| US-4391825-A | ALDOSE REDUCTASE INHIBITORS, FOR TREATING DIABETIC COMPLICATIONS | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-07-05 | — | — | US | disclosed |
| EP-0059596-A1 | N-Naphthoylglycine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIA4, GRM4, GRIK4 | MTNR1A 329/4885PDE4B 396/4885MTNR1B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.